Detalhe da pesquisa
1.
Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Br J Cancer
; 126(4): 576-585, 2022 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-34795408
2.
Detection of clinical progression through plasma ctDNA in metastatic melanoma patients: a comparison to radiological progression.
Br J Cancer
; 126(3): 401-408, 2022 02.
Artigo
em Inglês
| MEDLINE | ID: mdl-34373567
3.
First-in-human phase 1 study of budigalimab, an anti-PD-1 inhibitor, in patients with non-small cell lung cancer and head and neck squamous cell carcinoma.
Cancer Immunol Immunother
; 71(2): 417-431, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34216247
4.
A Phase I, First-in-Human Study of GSK2849330, an Anti-HER3 Monoclonal Antibody, in HER3-Expressing Solid Tumors.
Oncologist
; 26(10): e1844-e1853, 2021 10.
Artigo
em Inglês
| MEDLINE | ID: mdl-34132450
5.
Increased interdigitation zone visibility on optical coherence tomography following systemic fibroblast growth factor receptor 1-3 tyrosine kinase inhibitor anticancer therapy.
Clin Exp Ophthalmol
; 49(6): 579-590, 2021 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-33934469
6.
Adjuvant nivolumab versus ipilimumab in resected stage IIIB-C and stage IV melanoma (CheckMate 238): 4-year results from a multicentre, double-blind, randomised, controlled, phase 3 trial.
Lancet Oncol
; 21(11): 1465-1477, 2020 11.
Artigo
em Inglês
| MEDLINE | ID: mdl-32961119
7.
Detection and prognostic role of heterogeneous populations of melanoma circulating tumour cells.
Br J Cancer
; 122(7): 1059-1067, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32037400
8.
PD-L1 Expression on Circulating Tumor Cells May Be Predictive of Response to Pembrolizumab in Advanced Melanoma: Results from a Pilot Study.
Oncologist
; 25(3): e520-e527, 2020 03.
Artigo
em Inglês
| MEDLINE | ID: mdl-32162809
9.
Pamiparib in combination with tislelizumab in patients with advanced solid tumours: results from the dose-escalation stage of a multicentre, open-label, phase 1a/b trial.
Lancet Oncol
; 20(9): 1306-1315, 2019 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-31378459
10.
Programmed death ligand-1 expression in non-small cell lung cancer in a Western Australian population and correlation with clinicopathologic features.
Mod Pathol
; 32(4): 524-531, 2019 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-30401947
11.
Circulating tumour DNA (ctDNA) as a biomarker in metachronous melanoma and colorectal cancer- a case report.
BMC Cancer
; 19(1): 1109, 2019 Nov 14.
Artigo
em Inglês
| MEDLINE | ID: mdl-31727009
12.
Predictive value of PD-L1 and other clinical factors for chemoimmunotherapy in advanced non-small-cell lung cancer.
Future Oncol
; 15(20): 2371-2383, 2019 Jul.
Artigo
em Inglês
| MEDLINE | ID: mdl-31354046
13.
A Phase I study of the novel immunomodulatory agent PG545 (pixatimod) in subjects with advanced solid tumours.
Br J Cancer
; 118(8): 1035-1041, 2018 04.
Artigo
em Inglês
| MEDLINE | ID: mdl-29531325
14.
Correlation between circulating tumour DNA and metabolic tumour burden in metastatic melanoma patients.
BMC Cancer
; 18(1): 726, 2018 Jul 09.
Artigo
em Inglês
| MEDLINE | ID: mdl-29986670
15.
Medical Oncology Group of Australia position statement and membership survey on voluntary assisted dying.
Intern Med J
; 48(7): 774-779, 2018 07.
Artigo
em Inglês
| MEDLINE | ID: mdl-29984513
16.
Correction: Phase 1A/1B dose-escalation and -expansion study to evaluate the safety, pharmacokinetics, food effects and antitumor activity of pamiparib in advanced solid tumours.
Br J Cancer
; 126(2): 310, 2022 Feb.
Artigo
em Inglês
| MEDLINE | ID: mdl-34931042
17.
Combined BRAF and MEK inhibition versus BRAF inhibition alone in melanoma.
N Engl J Med
; 371(20): 1877-88, 2014 Nov 13.
Artigo
em Inglês
| MEDLINE | ID: mdl-25265492
18.
Survey of practices around pharmaceutical company funding for continuing professional development among medical oncologists and trainees in Australia.
Intern Med J
; 47(8): 888-893, 2017 Aug.
Artigo
em Inglês
| MEDLINE | ID: mdl-28485058
19.
Dabrafenib and trametinib versus dabrafenib and placebo for Val600 BRAF-mutant melanoma: a multicentre, double-blind, phase 3 randomised controlled trial.
Lancet
; 386(9992): 444-51, 2015 Aug 01.
Artigo
em Inglês
| MEDLINE | ID: mdl-26037941
20.
Cutaneous Metastatic Melanoma Resembling a Halo Nevus, in the Setting of PD-1 Inhibition.
Am J Dermatopathol
; 38(12): e159-e162, 2016 Dec.
Artigo
em Inglês
| MEDLINE | ID: mdl-27870733